The BCLI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BCLI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BCLI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View BCLI Detailed Price Forecast - CNN Money | View BCLI Detailed Summary - Google Finance | ||
View BCLI Detailed Summary - Yahoo! Finance | View BCLI Stock Research & Analysis - Zacks.com |
View BCLI Trends & Analysis - Trade-Ideas | View BCLI Major Holders - Barrons | ||
View BCLI Call Transcripts - NASDAQ | View BCLI Breaking News & Analysis - Seeking Alpha | ||
View BCLI Annual Report - CompanySpotlight.com | View BCLI OTC Short Report - OTCShortReport.com | ||
View BCLI Fundamentals - TradeKing | View BCLI SEC Filings - Bar Chart | ||
View Historical Prices for BCLI - The WSJ | View Performance/Total Return for BCLI - Morningstar | ||
View the Analyst Estimates for BCLI - MarketWatch | View the Earnings History for BCLI - CNBC | ||
View the BCLI Earnings - StockMarketWatch | View BCLI Buy or Sell Recommendations - MacroAxis | ||
View the BCLI Bullish Patterns - American Bulls | View BCLI Short Pain Metrics - ShortPainBot.com |
View BCLI Stock Mentions - StockTwits | View BCLI Stock Mentions - PennyStockTweets | ||
View BCLI Stock Mentions - Twitter | View BCLI Investment Forum News - Investor Hub | ||
View BCLI Stock Mentions - Yahoo! Message Board | View BCLI Stock Mentions - Seeking Alpha |
View Insider Transactions for BCLI - SECform4.com | View Insider Transactions for BCLI - Insider Cow | ||
View BCLI Major Holdings Summary - CNBC | View Insider Disclosure for BCLI - OTC Markets | ||
View Insider Transactions for BCLI - Yahoo! Finance | View Institutional Holdings for BCLI - NASDAQ |
View BCLI Stock Insight & Charts - FinViz.com | View BCLI Investment Charts - StockCharts.com | ||
View BCLI Stock Overview & Charts - BarChart | View BCLI User Generated Charts - Trading View |
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Posted on Tuesday April 16, 2024
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four years of maintaining top executive roles, Dr. Stacy Lindborg stepping down from the role of Co-CEO and will remain with BrainStorm as a member of its Board of Directors. These strategic management changes are being made as the Company prep
BCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…
Posted on Thursday April 11, 2024
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Receives SPA Agreement with FDA On April 9, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that it received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) on the design for a Phase 3b trial of NurOwn™ in amyotrophic lateral sclerosis
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
Posted on Thursday April 11, 2024
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it received a notification letter (the "Notification Letter on Compliance") on April 10, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), indicating that the Company has regained compliance with the minimum market value of listed securities requirement set forth under Nasdaq Listing Rule 5550(b)(2) (t
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
Posted on Wednesday April 10, 2024
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve. The paper, entitled "Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes", can be found online through the Muscle and Nerve website. This study suggests that debamestrocel or NurOwn®, an investigational cell therapy